Medipharm Labs completes first shipment to France

Executive Summary

• Medipharm Labs completed its first shipment to France, marking its entry into the European medical cannabis market following a production agreement with an international medicinal cannabis organization.
• The company highlights the significant growth potential of the French market, with conservative estimates projecting it to reach $187.6 million (U.S.) by 2025 and $213.3 million (U.S.) by 2030.
• As of Q3 2025, international medical cannabis accounted for 56% of total revenue, with an 83% year-over-year growth in international revenue driven by product portfolio expansion.

Key Details

• First Shipment: Completed first shipment to France, demonstrating the ability to meet stringent European regulatory standards for pharmaceutical-grade cannabis products.
• Market Projections: French medicinal cannabis market projected to grow from $187.6 million (U.S.) in 2025 to $213.3 million (U.S.) in 2030 under current regulatory conditions.
• Revenue Composition: International medical cannabis represented 56% of Medipharm's total revenue as of Q3 2025.
• Growth Metrics: Achieved 83% year-over-year growth in revenue for international medical cannabis.
• Global Footprint: The company now ships products to 10 countries globally.
• Strategic Partnerships: Expansion driven by strategic distribution and pharmaceutical partnerships leveraging industry-leading licenses from multiple regulatory authorities.

Notable Quotes

• "Medipharm's completion of our first production order and subsequent shipment to France marks our entry into one of Europe's most promising emerging medical cannabis markets. This achievement underscores our ability to establish new pathways to market and deliver pharmaceutical-grade products that meet stringent European standards." — David Pidduck, Chief Executive Officer